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This report presents the recommendations of the thirty-
eighth WHO Expert Committee on Drug Dependence 
(ECDD). The ECDD is responsible for the assessment of 
psychoactive substances for possible scheduling under 
the international drug control conventions. The ECDD 
reviews the therapeutic usefulness, the liability for abuse 
and dependence, and the public health and social harm 
of each substance. The ECDD will advise the Director-
General of WHO, to schedule or to amend the scheduling
status of a substance. The Director General will, as 
appropriate, communicate the recommendations to the
Secretary-General of the United Nations, who will in turn 
communicate the advice to the Commission on Narcotic 
Drugs (CND). 
The report summarizes the review of twelve substances 
and the ECDD recommendations for the scheduling of 
ten substances. Furthermore, the ECDD discussion and
recommendation for pre-reviews of pre-reviews of cannabis 
and its component substances are included in this report. 
The report also contains updates from international bodies 
concerned with controlled substances, as well as summaries 
of the follow up on the recommendations made at the
previous Committee meeting, and on the discussions of
prioritization of substances, surveillance systems of new 
psychoactive substances and terminology. Issues identified 
for consideration at future Expert Committee meetings are
also listed. 
The World Health Organization was established in 1948 as a specialized agency of the 
United Nations serving as the directing and coordinating authority for international 
health matters and public health. One of WHO’s constitutional functions is to 
provide objective and reliable information and advice in the field of human health, a 
responsibility that it fulfils in part through its extensive programme of publications. 
The Organization seeks through its publications to support national health strategies 
and address the most pressing public health concerns of populations around the world. 
To respond to the needs of Member States at all levels of development, WHO publishes 
practical manuals, handbooks and training material for specific categories of health 
workers; internationally applicable guidelines and standards; reviews and analyses of 
health policies, programmes and research; and state-of-the-art consensus reports that 
offer technical advice and recommendations for decision-makers. These books are 
closely tied to the Organization’s priority activities, encompassing disease prevention 
and control, the development of equitable health systems based on primary health 
care, and health promotion for individuals and communities. Progress towards better 
health for all also demands the global dissemination and exchange of information 
that draws on the knowledge and experience of all WHO’s Member countries and the 
collaboration of world leaders in public health and the biomedical sciences. To ensure 
the widest possible availability of authoritative information and guidance on health 
matters, WHO secures the broad international distribution of its publications and 
encourages their translation and adaptation. By helping to promote and protect health 
and prevent and control disease throughout the world, WHO’s books contribute to 
achieving the Organization’s principal objective – the attainment by all people of the 
highest possible level of health.
The WHO Technical Report Series makes available the findings of various international 
groups of experts that provide WHO with the latest scientific and technical advice on 
a broad range of medical and public health subjects. Members of such expert groups 
serve without remuneration in their personal capacities rather than as representatives 
of governments or other bodies; their views do not necessarily reflect the decisions 
or the stated policy of WHO. An annual subscription to this series, comprising about 
four to six such reports, costs CHF 150.00/US$ 80.00 (CHF 105.00/US$ 126.00 in 
developing countries). For further information, please contact: WHO Press, World 
Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 
3264; fax: +41 22 791 4857; email: bookorders@who.int; order online: http://www.
who.int/bookorders).
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Introduction 
The thirty-eighth meeting of the World Health Organization (WHO) Expert 
Committee on Drug Dependence (ECDD) took place in Geneva, Switzerland 
from 14 to 18 November 2016. Dr Suzanne Hill, Director, WHO Department 
of Essential Medicines and Health Products (EMP), opened the meeting. She 
welcomed all participants on behalf of the WHO Director-General.
 Dr Marie-Paule Kieny, Assistant Director-General, Health Systems 
and Innovation, of WHO, thanked the ECDD members for the time and effort 
they had dedicated to the thorough review of the substances on the agenda of 
this ECDD meeting. She outlined the central role of scientific evidence in the 
decision-making process of Expert Committees and in WHO’s normative and 
standard-setting role.
Dr Kieny reiterated the importance of the international drug control 
conventions and of the recommendations of the Special Session of United 
Nations General Assembly (UNGASS) on the world drug problem, that guide 
WHO’s work towards positioning health at the centre of responses to the world 
drug problem and achieving the health-related objectives of the Sustainable 
Development Goals (SDGs). She emphasized the need for WHO to work closely 
with the United Nations Office on Drugs and Crime (UNODC), the International 
Narcotics Control Board (INCB) and other global and regional entities, as well 
as Member States, to achieve efficient and successful implementation of the 
UNGASS operational recommendations and tackle the world drug problem.
Dr Kieny discussed that at its thirty-eighth meeting, the ECDD would 
assess 12 new psychoactive substances (NPS). WHO’s objective is not to review 
the hundreds of NPS reported globally to date, but to focus on the ones that 
are the most prevalent, persistent and harmful. To this end, a systematic and 
evidence-based prioritization of NPS had been carried out in advance of the 
thirty-eighth meeting of the ECDD and a number of Member States had 
contributed by sharing published and unpublished data.
 Dr Kieny noted that the Expert Committee would also discuss an update 
on cannabis and cannabis resin in light of the growing interest of Member States 
in its medical use and also in response to the 2009 Commission on Narcotic 
Drugs (CND) Resolution that requested WHO to provide regular updates on the 
cannabis plant and resin.
As recommended by the ECDD at its thirty-seventh meeting, the WHO 
Secretariat had collected new data and commissioned systematic reviews on 
medical use and on dependence and harm of cannabis and cannabis resin. The 
available scientific evidence and public health considerations would be the main 
criteria guiding the Committee’s recommendations, in particular because of the 
sensitive nature of the issue.
 In that regard, Dr Kieny reminded the Committee members that in 
the exercise of their function, they shall act as international experts serving 
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the Organization exclusively; in that capacity they shall not request or receive 
instructions from any government or authority external to the Organization. 
Furthermore, they shall disclose all circumstances that could give rise to a 
potential conflict of interest and in accordance with the mechanisms established 
by the Director-General for that purpose.
 Dr Gilles Forte, Coordinator, Policy, Governance and Knowledge 
Management, Department of EMP, provided the Committee with an overview 
of procedural matters. The international drug control conventions describe the 
mandate and roles of WHO. A key WHO role within this framework is to assess 
the therapeutic usefulness, the liability for abuse and dependence and the harm 
to health of any substance, pure chemical or plant material, and to advise the 
CND on whether or not substances should be placed under international control.
WHO also follows the relevant guidance of its governing bodies, in 
particular WHO’s Regulations for expert advisory panels and committees (1) as well 
as the Guidance on the WHO review of psychoactive substances for international 
control (2). 
Before the opening of the meeting, and in accordance with WHO policy, 
all members of the Expert Committee and all temporary advisers attending 
the meeting were asked to disclose any circumstances that could represent a 
potential conflict of interest (i.e. any interest that may affect, or may reasonably 
be perceived to affect, an expert’s objectivity and independence) in relation to the 
subject matter of the meeting.
Dr Simon D. Brandt declared that he was involved in the preparation of 
technical reports and presentations to the Scientific Committee of the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) on NPS and 
attended the EMCDDA risk assessment meeting on one of the substances – methyl 
N-{[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl}-3-methyl-L-valinate (MDMB-
CHMICA) – under consideration by the ECDD at its thirty-eighth meeting.
Dr Edmundus J.M. Pennings declared that he has been a member of the 
Committee for the Risk Assessment of NPS in the Netherlands since 1998. This 
committee carries out science-based risk assessments of NPS and advises the 
Dutch government on issues related to their misuse. Dr Pennings stated that the 
committee had never carried out a risk assessment for any of the substances that 
would be critically reviewed at the thirty-eighth meeting of the ECDD.
The disclosed interests were considered by the Secretariat of the thirty-
eighth ECDD as not in conflict with any issues to be discussed at the meeting 
or with the recommendations to be issued by the Expert Committee. No other 
interests declared by members of the Expert Committee were deemed relevant to 
the work of the group.
The Expert Committee elected a Chair, Co-Chair and Rapporteur. The 
Chair welcomed all participants and the agenda as proposed by the Secretariat 
was approved.
1. Briefings from international organizations on their work on the public health element 
of the world drug problem
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1. Briefings from international organizations on their work
on the public health element of the world drug problem
1.1 Update from the International Narcotics Control Board 
Dr Viroj Sumyai, Observer for the International Narcotics Control Board 
(INCB) and Chair of the INCB Standing Committee on Estimates, informed the 
Committee about the role and functions of the INCB. Established by the Single 
Convention on Narcotic Drugs, 1961 (3), the INCB consists of 13 members who 
are elected by the Economic and Social Council and who serve in their personal 
capacity. Three members with medical, pharmacological or pharmaceutical 
experience are elected from a list of candidates nominated by WHO and 10 
members are elected from a list of candidates nominated by governments.
In his update, Dr Viroj Sumyai referred to the recent annual report of the 
INCB and its thematic chapter on the challenges and opportunities of international 
drug control. This chapter stresses that concern for health and welfare should be 
at the core of drug policy and action at the national and international levels. In 
addition, the INCB calls for balance in implementing drug control policy and 
for the observance of human rights standards for treatment and rehabilitation of 
drug users.
Ms Beate Hammond briefed the ECDD on the INCB special report on 
ensuring adequate access to internationally controlled drugs. Noting that there 
were still large disparities in the consumption of drugs worldwide, the report 
highlights the main impediments to better availability. These include fear of 
addiction and lack of awareness on the proper use of internationally controlled 
drugs for medical purposes, as well as constraints on both human and financial 
resources.
The report makes recommendations to governments on how this situation 
can be improved. To bridge the knowledge gap, for example, it is necessary to 
develop and implement educational programmes and disseminate information 
to overcome cultural resistance, where necessary. Many countries continue to 
experience difficulties in properly estimating their needs for opioid analgesics 
and psychotropic substances and in monitoring their consumption. The report 
therefore calls on governments to make use of the INCB/WHO Guide on 
estimating requirements for substances under international control (4). In addition, 
governments should review national legislation, regulatory and administrative 
mechanisms and procedures, including domestic distribution channels, with the 
aim of simplifying and streamlining the processes. This would involve removing 
unduly restrictive regulations and impediments to ensure accessibility while 
maintaining adequate control systems.
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1.2 Update from the United Nations Office on Drugs and Crime
Dr Justice Tettey, Observer for UNODC, informed the Committee that NPS 
continued to appear at a fast pace on drug markets worldwide and their use 
had been associated with adverse events, including fatalities. To date, 730 NPS 
have been reported, in 102 Member States and territories, to the UNODC 
Early Warning Advisory (EWA). The market continues to be characterized by 
heterogeneity in the nature and scope of the problem, the transient nature of 
some of the substances reported and a paucity of information on public health 
harm. A recent trend in the marketing of blends or mixtures of NPS, makes the 
interpretation of data on their associated harm particularly challenging. UNODC 
research and trend analysis contributes to improving the understanding of, and 
shaping the response to, the NPS issue through knowledge products and early 
warnings. These efforts will continue with the publication of an extended chapter 
on the latest trends and developments in NPS and amphetamine-type stimulants 
(ATS) markets in the 2017 World Drug Report.
Dr Tettey reported that under its global Synthetics Monitoring: Analysis, 
Reporting and Trends (SMART) programme, UNODC continues to monitor, 
analyse and share information on NPS at the global level. Its EWA on NPS is 
actively used by Member States and international organizations, such as WHO, 
in the context of the selection of substances for consideration by the ECDD and 
to inform the scheduling decisions of the CND.
He emphasized that reducing the supply of NPS through scheduling under 
the international conventions continues to be a viable measure. In 2015, the CND 
decided to place 10 NPS under international control. Pursuant to these scheduling 
decisions, UNODC supported their implementation by Member States through the 
development and dissemination of a series of recommended laboratory methods 
of analyses. It provided more than 1400 units of chemical reference materials 
for these substances to forensic institutions in 55 countries. In addition, selected 
substances were introduced in UNODC’s international collaborative exercises, 
a biannual proficiency test scheme for national drug laboratories. This scheme 
currently supports more than 250 laboratories from 70 countries, to enhance 
their preparedness to identify these threats. To further aid in implementation of 
the scheduling decisions, UNODC revised its Multilingual dictionary of narcotic 
drugs and psychotropic substances under international control (5), the Multilingual 
dictionary of precursors and chemicals frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances under international control (6) and the 
Terminology and information on drugs (7).
Dr Tettey described a comprehensive programme of training to enhance 
law enforcement capacity in identifying NPS and substances under international 
control that was implemented across the Pacific island states, south-east Asia, 
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south Asia and west Africa in 2015, and in central Asia and south Asia in 2016. 
These included the deployment of modern hand-held technologies, e.g. Raman 
and Fourier transform infrared spectrometers for training in field testing for 
drugs and precursors, to cope with the unprecedented numbers of reported NPS.
He emphasized that a health-based approach to the NPS problem is 
essential to support the tenet of the international drug control conventions – 
protecting the health and welfare of humankind. In September 2016, UNODC, in 
collaboration with WHO, convened a meeting of experts on substance disorders 
from around the world to explore new frontiers of health protection with regard 
to NPS. The participants discussed key aspects of NPS, in particular diagnostic 
approaches and treatment options, with the goal of developing a practical tool to 
be used by clinicians worldwide.
Dr Tettey went on to describe the continuing efforts to operationalize 
the recommendations on NPS outlined in the outcome document of the 
UNGASS 2016. Specifically, the third UNODC-WHO Expert Consultation in 
Geneva in May 2016 focused on practical approaches to identifying the most 
harmful, prevalent and persistent NPS for international action. Further to this, 
UNODC has enhanced its engagement with the global forensic toxicology 
community, as a first step towards addressing the paucity of data on the harm 
of NPS. Global trends in emergence of NPS continue to evolve rapidly. The past 
few years have seen the emergence of a number of synthetic opioids, including 
fentanyl analogues. While these only account for approximately 1% of all NPS 
reported to UNODC, the associated harm to public health has been immense. 
In this context, on 25 October 2016, the UN Secretary-General notified states 
parties of the communication sent by the United States of America, further to 
the provisions in the United Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988, to initiate steps to add N-phenethyl-
4-piperidinone (NPP) and 4-anilino-N-phenethylpiperidine (ANPP), common 
precursors in the synthesis of fentanyl and a number of its analogues, to the tables 
of the 1988 Convention.
He noted that further to the CND Decision 58/2 (2015), UNODC 
continues to monitor the illicit trafficking and use of ketamine, and to share its 
findings with WHO.
The Committee was informed that, at its fifty-ninth regular session in 
March 2016, the CND decided to place seven NPS under international control 
under the relevant schedules of the Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol, and the Convention on Psychotropic Substances 
of 1971 (3, 8). On 17 May 2016, the Secretary-General notified states parties of 
these scheduling decisions. The revised schedules under the 1961 and the 1971 
Conventions came into effect on 18 May 2016 and 13 November 2016, respectively.
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Dr Tettey concluded that UNODC will continue to extend support to 
Member States through research and trend analysis to improve understanding of 
the NPS problem. It will also provide the relevant tools and services to support 
Member States’ implementation of the new scheduling decisions.
1.3 Update from the WHO Department of Essential Medicines 
and Health Products
Dr Gilles Forte, Coordinator, Policy, Governance and Knowledge Management, 
provided an update from the WHO EMP.
Dr Forte emphasized that WHO is committed to implementing the 
UNGASS recommendations related to health, and will work closely with 
UNODC, the INCB, civil society and other international and regional partners 
to fulfil this commitment.
The United Nations General Assembly Resolution S-30/1, adopted on 
19 April 2016 (9), underscores that the availability of internationally controlled 
drugs for medical and scientific purposes remains low to non-existent in many 
countries and emphasizes the need for international cooperation to promote 
measures to improve access to these medicines. 
Controlled medicines are needed to alleviate pain and suffering, 
enable surgery, treat physical and mental health issues, support dignified and 
comfortable end-of-life care, help people to overcome addiction and to save lives. 
Health systems cannot work effectively without essential controlled medicines. 
However, despite their vital importance, access to controlled medicines remains 
inadequate around the world.
Dr Forte reiterated that the importance of access to controlled medicines 
for public health has been emphasized in several World Health Assembly (WHA) 
resolutions. These WHA resolutions reflect Member States’ commitment to 
ensuring access to controlled medicines for palliative care (WHA67.19), for 
emergency and essential surgical care and anaesthesia (WHA68.15) and for 
epilepsy (WHA68.20). These resolutions also provide WHO with a strong mandate 
to support Member States’ efforts to address barriers to access, while preventing 
risks for diversion and abuse. Barriers to access have been well addressed in the 
UNGASS outcome document. They relate to lack of knowledge on efficacy, safety 
and appropriate use of medicines; unduly restrictive regulations on supply and 
dispensing; and inefficiency of supply chains, which leads to poor availability and 
affordability of medicines.
As part of its standard-setting mandate, and based on rigorous scientific 
evidence, the WHO Secretariat undertakes regular reviews of the efficacy and 
safety of medicines, including controlled medicines. These reviews inform 
recommendations for the inclusion in or exclusion of medicines from the WHO 
Model List of Essential Medicines (EML). The WHO Secretariat had carried out 
1. Briefings from international organizations on their work on the public health element 
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a review of medicines for pain that could be considered for addition to the WHO 
EML by the WHO Expert Committee on the Selection and Use of Essential 
Medicines at its meeting in March 2017. Also, the WHO Secretariat has developed 
guidelines for the management of persisting pain in children and is currently 
developing new guidelines for the management of cancer pain in adults.
In collaboration with UNODC and the Union for International Cancer 
Control, WHO is part of the Joint Global Programme on Access to Controlled 
Drugs for Medical Purposes while Preventing Diversion and Abuse, in particular 
for the management of pain. The programme is currently supported by Australia 
and Belgium and implemented in the Democratic Republic of the Congo, Ghana 
and Timor-Leste. It aims to support countries to identify potential barriers to 
access, through the assessment of policies, legislation, and the supply chain, and 
to identify strategies and interventions that will improve practices and enhance 
capacity-building.
Dr Forte indicated that work with countries will also focus on the use of 
tools and guidance to ensure more accurate quantification of requirements for 
controlled medicines; to explore measures to improve the efficiency and integrity 
of supply chains; and to support the development of balanced national policies on 
controlled substances that ensure availability and accessibility, while preventing 
misuse and abuse.
1.4 Update from the WHO Department of Mental Health and 
Substance Abuse
Dr Vladimir Poznyak, Coordinator, Management of Substance Abuse unit of the 
Department of Mental Health and Substance Abuse (MSB/MSD), informed the 
Committee about the outcomes of the UNGASS on the world drug problem (April 
2016). He also described WHO’s work on three of the five public health pillars, 
and critical elements of the public health dimension of the world drug problem 
as described in the report by the Secretariat to the sixty-ninth World Health 
Assembly. These three pillars are: (1) prevention of drug use and reduction of 
vulnerability and risks; (2) treatment and care for people with drug use disorders 
and (3) monitoring and evaluation.
Dr Poznyak informed the Committee about recent MSB/MSD activities 
including the publication and dissemination of the report on the health and 
social consequences of non-medical use of cannabis, of a policy brief on drug 
use and road safety and of new estimates of drug-attributable disease burden. 
The epidemics of opioid overdose deaths in several countries and the misuse 
and abuse of psychoactive prescription medicines continue to present significant 
public health challenges. WHO’s new estimates of drug-attributable disease 
burden indicate that more than 450 000 deaths globally are attributed to illicit 
drug use, including cannabis use. The main conditions contributing to drug-
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attributable deaths are drug use disorders, hepatitis C virus (HCV), human 
immunodeficiency virus (HIV), road traffic injuries and suicide. The impact of 
cannabis use on mental health and on the health of people other than regular 
cannabis users requires further research. The increasing availability of cannabis 
in many countries may have a negative impact on population health and needs to 
be monitored closely. It is still difficult to quantify the impact of NPS on health 
at a population level and specific strategies need to be developed to fill this gap. 
The draft version of the revised International Classification of Diseases (ICD-
11) provides additional possibilities for coding and reporting health conditions 
resulting from the use of synthetic cannabinoids and cathinones, as well as the 
use of cocaine, 3,4-methylenedioxymethamphetamine (MDMA), phencyclidine; 
1-(1-phenylcyclohexyl)piperidine (PCP) and related drugs.
1.5 Update from the WHO Department of HIV/AIDS 
Dr Andrew Ball, Senior Adviser on Strategy, Policy and Equity in the WHO 
Department of HIV and the Global Hepatitis Programme provided a brief 
overview of HIV and viral hepatitis as global public health issues for people who 
use drugs, particularly for those who inject drugs. People who inject drugs are 
up to 24 times more likely to acquire HIV than the general population and an 
estimated 10 million people who inject drugs have chronic HCV infection. WHO’s 
HIV department has synthesized the evidence for a public health approach to 
injecting drug use, based on harm reduction principles, and has developed 
normative guidance on HIV and hepatitis prevention, diagnosis, treatment and 
care. A comprehensive package of evidence-based interventions to reduce the 
harm associated with (injecting) drug use has been outlined in a technical guide 
issued jointly by WHO, UNAIDS and UNODC in 2009 and revised in 2012 (10).
Given the evidence of the utility of harm reduction approaches in 
addressing drug use and drug use disorders and in improving broader health 
outcomes, such interventions need to be a key component of a comprehensive 
response to substance use. There is also strong evidence that programmes that 
reduce the short- and long-term harm to substance users benefit the entire 
community through addressing HIV and hepatitis epidemics, and reducing crime 
and public disorder, in addition to the benefits that accrue from the inclusion into 
mainstream life of previously marginalized members of society.
In 2016, the Global Health Sector Strategies on HIV and viral hepatitis 
were adopted by the World Health Assembly. Both strategies include harm 
reduction as an essential set of interventions that should be delivered through 
national health programmes and supported by national health budgets. WHO 
therefore continues to advocate for a public health approach to the drug problem 
at major global events such as the UN General Assembly High-Level Meeting 
1. Briefings from international organizations on their work on the public health element 
of the world drug problem
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on Ending AIDS and the UNGASS on the world drug problem, as well as the 
International AIDS Conference and the Global Hepatitis Summit. Furthermore, 
the SDGs’ targets will not be met if harm reduction is not brought to scale and if 
people who use drugs are not accessing HIV prevention, testing, treatment and 
care services.
After having developed comprehensive normative guidance, WHO 
is now focusing on providing technical support to countries implementing a 
public health sector response. Countries are also being supported to improve 
their strategic information systems and in the use of standardized indicators to 
monitor progress and measure services access and coverage of people who inject 
drugs along the HIV and hepatitis prevention, testing and treatment cascades.
The Department of HIV/AIDS also manages a special web page on access 
to controlled medicines such as methadone, buprenorphine and oral morphine 
as part of the AIDS Medicines and Diagnostics Services database.
Finally, the Dr Ball described the work of the Department of HIV/AIDS 
on outlining the structural barriers that impede implementation and scale-up of 
services for people whose behaviour tends to be criminalized, including for people 
who use and inject drugs. Measures to address these barriers include the revision 
of laws and legislation to promote a public health approach as an alternative 
to criminalization of drug using behaviours, stigma and discrimination in the 
health sector, as well as appropriate funding for harm reduction.
10
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2. Principles for prioritizing and assessing substances as 
part of ECDD’s work
Dr Eda Lopato, Technical Officer, Innovation, Access and Use, EMP, briefed the 
Committee and the observers on the process of prioritization of psychoactive 
substances to be reviewed by the ECDD.
Dr Lopato discussed the recent CND resolution 59/8 (2016) entitled 
“Promotion of measures to target new psychoactive substances and amphetamine-
type stimulants” (11), which recognized the added value of WHO in the 
international response to NPS and noted WHO’s efforts to monitor and carry out 
regular annual reviews of NPS. The resolution invited,
WHO, with the support of the UNODC, relevant regional organizations and Member 
States, to continue conducting regular, efficient, transparent and timely reviews of 
the most harmful, prevalent and persistent new psychoactive substances and to use 
the potential impact of toxicity at both the population and individual levels as the 
primary factor in prioritizing substances for review.
Dr Lopato described the challenges faced when prioritizing substances 
to be reviewed by the ECDD. These challenges include the transient nature of 
psychoactive substances and the changing patterns of supply as well as countries’ 
lack of capacity and expertise for the identification of substances (e.g. fentanyls), 
which leads to underreporting of use, adverse events and drug seizures. The 
situation is further complicated by polydrug use that makes the evaluation of 
harm related to each substance difficult, and the marketing of mixtures of 
different substances hampers the interpretation of toxicological data. In addition, 
published data on harm to health, adverse effects, abuse and dependence potential 
for NPS are scarce.
When prioritizing substances for review by the Committee, the WHO 
ECDD Secretariat should proactively search for and analyse data on harm to 
health (e.g. non-fatal or fatal intoxications), on abuse and dependence potential, 
and on prevalence (e.g. Is it found in more than one country or region?). To 
facilitate access to information that would assist in prioritization of substances 
for discussion at the thirty-eighth meeting of the ECDD, the Secretariat had 
collaborated with UNODC, the INCB, the EMCDDA, Uppsala Monitoring 
Centre (UMC) and with Member States. A thorough analysis of the data obtained 
had led to the selection of a final list of 12 substances to be reviewed.
3. Update from the first Informal Working Group of the ECDD
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3. Update from the first Informal Working Group of the 
ECDD
Professor Bruna Brands (Chair of the ECDD) provided an overview of the 
activities of the first Informal Working Group of the ECDD, which met in Geneva, 
Switzerland, on 5 and 6 May 2016.
Professor Brands explained that the working group was composed of six 
members of the thirty-seventh ECDD and that its aim was to propose improved 
methods related to the review of substances as addressed in the Guidance on the 
WHO review of psychoactive substances for international control (2).
Aspects such as the prioritization process for NPS and the development of 
training materials for new members of the ECDD and for temporary advisers were 
addressed. A session on terminologies and on proposed classes of psychoactive 
substances was organized in the context of the ongoing revisions of ICD-11.
The working group also discussed the revision of the template for the 
critical review reports that had been used for the first time for the thirty-eighth 
meeting of the ECDD. ECDD members who carried out critical reviews of 
substances generally agreed that the new template was an improvement compared 
to the ones from previous ECDDs in terms of the greater clarity of the content 
for each section and the harmonization of information provided in the reviews.
Professor Brands also informed the Committee that the working group’s 
revised template for the WHO questionnaire for psychoactive substances, which 
is used for collection of data from Member States, was used for the first time for 
the thirty-eighth meeting. The wording of this questionnaire had been simplified 
and clarified.
At the close of Professor Brands’ presentation, a suggestion was put 
forward that the Secretariat collect subsequent questions by Committee members 
regarding terminology or the review template in general and put them to the 
working group. Professor Brands stated that comments and questions from 
members and temporary advisers would be welcomed and encouraged. The 
working group would then try to address them during its next meeting.
12
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4. Follow-up on recommendations made by the ECDD at 
its thirty-seventh meeting
Dr Eda Lopato gave an overview of the follow-up on the recommendations made 
at the thirty-seventh meeting of the ECDD and informed the Committee about 
the decisions of the CND (2016).
 The thirty-seventh meeting of the WHO ECDD had taken place in 
Geneva, Switzerland from 16 to 20 November 2015 and the Committee had 
recommended that seven of the eight substances it had critically reviewed 
be placed under international control and that one substance be kept under 
surveillance. The recommendations on the following substances to be placed 
under international control were conveyed to the Secretary-General of the United 
Nations and discussed at the fifty-ninth session of the CND in March 2016.
4.1 Acetylfentanyl
As recommended by the ECDD at its thirty-seventh meeting, on 18 March 
2016 the CND decided to include acetylfentanyl in Schedules I and IV of the 
Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol 
(Decision 59/1).
4.2 MT-45
As recommended by the ECDD at its thirty-seventh meeting, on 18 March 2016 
the CND decided to include MT-45 in Schedule I of the Single Convention on 
Narcotic Drugs of 1961 as amended by the 1972 Protocol (Decision 59/2).
4.3 para-Methoxymethylamphetamine (PMMA)
As recommended by the ECDD at its thirty-seventh meeting, on 18 March 
2016 the CND decided to include para-methoxymethylamphetamine (PMMA) 
in Schedule I of the Convention on Psychotropic Substances of 1971 (Decision 
59/3).
4.4 α-Pyrrolidinovalerophenone (α-PVP)
As recommended by the ECDD at its thirty-seventh meeting, on 18 March 2016 
the CND decided to include α-pyrrolidinovalerophenone (α-PVP) in Schedule II 
of the Convention on Psychotropic Substances of 1971 (Decision 59/4).
4. Follow-up on recommendations made by the ECDD at its thirty-seventh meeting
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4.5 para-Methyl-4-methylaminorex (4,4´-DMAR)
As recommended by the ECDD at its thirty-seventh meeting, on 18 March 2016 
the CND decided to include para-methyl-4-methylaminorex (4,4´-DMAR) in 
Schedule II of the Convention on Psychotropic Substances of 1971 (Decision 
59/5).
4.6 Methoxetamine (MXE)
As recommended by the ECDD at its thirty-seventh meeting, on 18 March 
2016 the CND decided to include methoxetamine (MXE) in Schedule II of the 
Convention on Psychotropic Substances of 1971 (Decision 59/6).
4.7 Phenazepam
As recommended by the ECDD at its thirty-seventh meeting, on 18 March 2016 
the CND decided to include phenazepam in Schedule IV of the Convention on 
Psychotropic Substances of 1971 (Decision 59/7).
14
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5. Critical review of psychoactive substances
The review of psychoactive substances by WHO is carried out in two steps. The 
first step is referred to as pre-review; this is a preliminary review carried out by 
the Committee to determine whether or not a fully documented review (critical 
review) of the substance is required. If a preceding meeting of the Committee 
found that a critical review of a substance is warranted, the Secretariat will prepare 
such a review for the next meeting of the Committee. However, a pre-review 
is not always needed and in certain cases a critical review can be undertaken 
directly.
According to the Guidance on the WHO review of psychoactive substances 
for international control (2) “a critical review is initiated by the Expert Committee 
in any of the following cases:
 (1) there has been notification from a Party to the 1961 Single Convention 
on Narcotic Drugs and the 1971 Convention on Psychotropic 
Substances concerning the scheduling of a substance;
 (2) there has been an explicit request from CND to review a substance;
 (3) a pre-review of a substance has resulted in an Expert Committee 
recommendation for critical review; or
 (4) information is brought to WHO’s attention that a substance is 
clandestinely manufactured, of especially serious risk to public health 
and society, and of no recognized therapeutic use by any Party.
In respect of case (4), if therapeutic use of the substance is confirmed 
subsequently by any Party, the substance shall be subjected to a pre-review.”
5.1 U-47700
Substance identification
Chemically, U-47700 is 3,4-dichloro-N-(2-dimethylamino-cyclohexyl)-N-
methyl-benzamide. U-47700 has two chiral centres resulting in four isomers; cis- 
and trans-conformations, each of which has two enantiomers (cis, 1R,2R, and 
1S,2S; trans, 1R,2S and 1S,2R). 
Previous review
U-47700 has not previously been pre-reviewed or critically reviewed by the 
Committee. A direct critical review was proposed based on information brought 
to the attention of WHO that U 47700 is clandestinely manufactured, poses a risk 
to public health and society, and has no recognized therapeutic use by any Party.
5. Critical review of psychoactive substances
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Similarity to known substances and effects on the central nervous system
The closest controlled substance that is structurally related to U-47700 is AH-
7921, and they are structural isomers of one another. AH-7921 is controlled as a 
Schedule I drug under the Single Convention on Narcotic Drugs, 1961, as amended 
by the 1972 Protocol, in 2015. U-47700 binds and has functional activity at the 
mu opioid receptor and at the delta opioid receptor. It has antinociceptive activity 
in mice, with about 7.5 times the potency of morphine. Similar to morphine, 
case reports indicate that it produces pinpoint pupils, respiratory depression, 
cyanosis and depressed consciousness that is clinically reversible with naloxone. 
Confirmed fatalities (>15) associated with the use of U-47700 have occurred in 
Europe and in the United States.
Dependence potential
No controlled laboratory studies in animals or humans have been reported 
regarding the dependence effects of U-47700. Users, however, report the 
induction of tolerance and the emergence of withdrawal signs and symptoms 
upon discontinuing use of U-47700, suggestive of physical dependence.
Actual abuse and/or evidence of likelihood of abuse
No controlled laboratory studies in animals or humans have been reported 
regarding the abuse potential of U-47700. U-47700, however, is aggressively 
marketed on the Internet, often as a heroin or an oxycodone substitute, as itself, or 
in combination with other drugs. There have also been many seizures in Europe 
and in North America, some single seizures involving hundreds of pills. Users 
report administering U-47700 via the oral, insufflation, intravenous and rectal 
routes, and via an inhaler using a liquid solution. Some countries have placed 
U-47700 under national control, and recently (14 November 2016) the United 
States placed U-47700 under its Controlled Substances Act stating that this was 
necessary to avoid an imminent hazard to public safety.
Therapeutic usefulness
Although investigated preclinically as an analgesic, U-47700 has no history 
as a marketed medical product, nor are there any known current marketing 
authorizations for it as a medicinal product.
Recommendation
U-47700 (3,4-dichloro-N-(2-dimethylamino-cyclohexyl)-N-methyl-benzamide) 
is a compound liable to similar abuse and with similar ill effects to controlled 
opioids such as morphine and AH-7921 that are included in Schedule I of the 
Single Convention on Narcotic Drugs of 1961. It has no recorded therapeutic use, 
16
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and its use has resulted in fatalities. There is sufficient evidence that it is being 
or is likely to be abused so as to constitute a public health and social problem 
warranting the placing of the substance under international control. Thus, 
because it meets the required condition of similarity, it is recommended that 
U-47700 be placed in Schedule I of the Single Convention on Narcotic Drugs, 
1961, as consistent with Article 3, paragraph 3 (iii) of that Convention in that the 
substance is liable to similar abuse and productive of similar ill effects to drugs 
in Schedule I.
5.2 Butyrfentanyl (butyrylfentanyl)
Substance identification
Chemically, butyrfentanyl is N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]
butanamide.
Previous review
Butyrfentanyl has not been previously pre-reviewed or critically reviewed by the 
Committee. A direct critical review was proposed based on information brought 
to the attention of WHO that butyrfentanyl is clandestinely manufactured, poses 
a risk to public health and society, and has no recognized therapeutic use by any 
Party.
Similarity to known substances and effects on the central nervous system
Butyrfentanyl contains a carboxamide group that can be easily hydrolysed 
in strong acid or strong base when heated and subsequently converted by 
condensation into another carboxamide such as fentanyl and to other fentanyls. 
Fentanyl is a Schedule I drug under the UN Single Convention on Narcotic Drugs, 
1961. Similar to morphine, butyrfentanyl binds and has functional activity at 
the mu opioid receptor and produces antinociceptive activity in chemical and 
thermal assays in mice, with a potency about 1.5 times that of morphine and 30 
times less than that of fentanyl. Case studies report clinical features that include 
typical opioid symptoms such as respiratory depression, apnoea and loss of 
consciousness, and one report indicated responsiveness to naloxone.
Dependence potential
Butyrfentanyl demonstrates cross-dependency in the morphine-dependent 
rhesus monkey. There are no reports of controlled studies of physical dependence 
or cross-dependency in human subjects.
5. Critical review of psychoactive substances
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Actual abuse and/or evidence of likelihood of abuse
There are no known reports of controlled studies of abuse potential in humans 
or laboratory animals. Butyrfentanyl, however, is actively sold through Internet 
websites. It has been associated with several drug seizures, and with fatal and 
non-fatal intoxications both in Europe and the United States. Current estimates of 
use are likely to be underestimates because butyrfentanyl is not included in most 
drug screens. Routes of administration include insufflation, rectal, intravenous 
and sublingual use. Re-dosing is apparently common.
Therapeutic usefulness
There are no known approved therapeutic applications for butyrfentanyl.
Recommendation
Butyrfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]butanamide) is a 
compound liable to similar abuse and with similar ill effects to controlled opioids 
such as morphine and fentanyl that are included in Schedule I of the Single 
Convention on Narcotic Drugs, 1961. It can also be converted into fentanyl. It 
has no recorded therapeutic use and its use has resulted in fatalities. There is 
sufficient evidence that it is being or is likely to be abused so as to constitute a 
public health and social problem warranting the placing of the substance under 
international control. Thus, because it meets either of the required conditions of 
similarity or convertibility, it is recommended that butyrfentanyl be placed in 
Schedule I of the Single Convention on Narcotic Drugs, 1961, as consistent with 
Article 3, paragraph 3 (iii) of that Convention, in that the substance is liable to 
similar abuse and productive of similar ill effects to drugs in Schedule I.
5.3 4-Methylethcathinone (4-MEC)
Substance identification
Chemically, 4-methylethcathinone (4-MEC) is 2-(ethylamino)-1-(4-
methylphenyl)propan-1-one. 4-MEC has a chiral centre giving rise to an 
enantiomeric pair of (S)-4-MEC and (R)-4-MEC isomers.
Previous review
A critical review report on 4-MEC was discussed in June 2014 at the thirty-
sixth meeting of the WHO ECDD. The Committee recommended that 4-MEC 
not be placed under international control at that time due to insufficiency of 
data regarding dependence, abuse and risks to public health, but be kept under 
18
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surveillance. 4-MEC continues to appear as a psychostimulant with monoamine 
transporter activity with indications of abuse liability. New data that had emerged 
from in vitro and in vivo studies since the thirty-sixth ECDD meeting prompted 
the current critical review.
Similarity to known substances and effects on the central nervous system
4-MEC has a homologue, mephedrone (4-methylmethcathinone), which is 
listed as a Schedule II substance under the 1971 United Nations Convention on 
Psychotropic Substances. Similar to controlled psychostimulants, 4-MEC elevates 
extracellular neurotransmitter levels, most notably, dopamine, norepinephrine 
(noradrenaline) and serotonin. Also, in rodents, 4-MEC increases locomotor 
activity and produces sensitization, fully substitutes for the discriminative 
stimulus effects of cocaine and (in one of two reports) also of methamphetamine, 
establishes conditioned place preference, and reduces thresholds of intracranial 
self-stimulation. User reports of negative effects associated with 4-MEC mention 
excessive sweating, nausea, vomiting, jaw clenching, heart palpitations, loss 
of sight and migraine. The number of case reports that demonstrate a causal 
relationship between 4-MEC consumption and fatal intoxication is limited. This 
profile is consistent with amphetamine-like effects and it is likely that 4-MEC 
would produce adverse effects consistent with those associated with amphetamine.
Dependence potential
No controlled laboratory studies of the dependence potential of 4-MEC in animal 
or human subjects have been reported. Urge to re-dose when using 4-MEC was 
considered weak and short-lived with low incidence of negative after-effects 
(compared to mephedrone), although users with a history of synthetic cathinone 
use and less potent experiences with 4-MEC reported higher and more frequent 
dosing.
Actual abuse and/or evidence of likelihood of abuse
The ability of 4-MEC to occasion the discriminative stimulus effects of cocaine, 
and at least in one study, methamphetamine, suggests the ability to produce 
their subjective effects and associated abuse potential. 4-MEC’s ability to induce 
conditioned place preference and reduce intracranial self-stimulation thresholds, 
and to increase locomotor activity and produce sensitization to it, is consistent 
with this prediction. Controlled studies on the abuse potential of 4-MEC have 
not been conducted in humans. 4-MEC has been detected worldwide and is 
marketed as a “research chemical”; it has also been detected as a constituent in 
branded products available for purchase via the Internet and from brick-and-
mortar shops. Responses to the UNODC questionnaire on NPS (up to 2012) 
revealed that 4-MEC was ranked fourth with regard to numbers of reports 
5. Critical review of psychoactive substances
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received. User reports suggest that 4 MEC produces euphoria, a sense of well-
being and psychostimulant effects. A survey of a group of injecting drug users 
of NPS reported that 4-MEC was injected more often per day compared to what 
might be expected from heroin use. A number of countries in various regions 
have placed 4-MEC under national control.
Therapeutic usefulness
There are no known approved therapeutic applications for 4-MEC.
Recommendation
The Committee considered that the degree of risk to public health and society 
associated with the abuse of 4-MEC (2-(ethylamino)-1-(4-methylphenyl)propan-
1-one) is substantial. Therapeutic usefulness has not been recorded. It recognized 
that 4-MEC has similar abuse and similar ill-effects to substances in Schedule 
II of the UN Convention on Psychotropic Substances of 1971. The Committee 
considered that there is sufficient evidence that 4-MEC is being or is likely to 
be abused so as to constitute a public health and social problem warranting the 
placing of the substance under international control. As per the Guidance on the 
WHO review of psychoactive substances for international control (2), higher regard 
was accorded to the substantial public health risk than to the lack of therapeutic 
usefulness. The Committee recommended that 4-MEC be placed in Schedule II 
of the UN Convention on Psychotropic Substances of 1971.
5.4 3-Methylmethcathinone (3-methyl-N-methylcathinone; 
3-MMC)
Substance identification
Chemically, 3-MMC is 2-(methylamino)-1-(3-methylphenyl)propan-1-one. 
3-MMC contains a chiral centre at the C-2 carbon of the propane side chain, so 
two enantiomers exist: (R)-3-MMC and (S)-3-MMC.
Previous review
3-MMC has not previously been pre-reviewed or critically reviewed. A direct 
critical review was proposed based on information brought to the attention of 
WHO that 3-MMC is clandestinely manufactured, poses a serious risk to public 
health and society, and has no recognized therapeutic use by any Party.
Similarity to known substances and effects on the central nervous system
3-MMC is a positional isomer of 4-methylmethcathinone (4-MMC, mephedrone), 
which is a Schedule II substance under the Convention on Psychotropic Substances 
20
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of 1971. 3-MMC, however, is not readily converted into 4-MMC. There has 
been one controlled animal pharmacological study of 3-MMC. Data from case 
reports (including clinically described intoxications) and user reports indicate 
that 3-MMC displays similar properties to mephedrone and amphetamines. 
Adverse effects following its use have included tachycardia, agitation, reduced 
level of consciousness, dilated pupils, hallucinations, diaphoresis, seizures and 
hyperthermia. Users have also reported insomnia, difficulties in concentrating, 
and tingling in the arms and legs. Hospitalizations have been reported, with a 
few being due to 3-MMC use alone. Fatalities involving polydrug abuse in which 
3-MMC was detected have been reported, but its toxicological significance was 
low or unclear.
Dependence potential
No controlled studies on dependence potential of 3-MMC have been conducted 
in humans or laboratory animals.
Actual abuse and/or evidence of likelihood of abuse
No controlled laboratory studies of abuse liability have been conducted in animals 
or humans. In response to the WHO questionnaire for review of psychoactive 
substances, several countries reported abuse of 3-MMC, as a recreational drug, 
for its psychoactive properties. Most reports noted that the negative impact 
on health originating from consumption was substantial. In one country that 
administered a self-reporting questionnaire, 67.9% of respondents indicated they 
had tried 3-MMC, and 26.8% indicated that they had been using it for more 
than one year. In a study in another country, 66 instances of driving under the 
influence of drugs (DUID) involved 3-MMC; in 19 of these cases, 3-MMC was 
determined to be the only substance present. 3-MMC is generally administrated 
by insufflation, inhalation, orally or by injection. User-reported effects include 
production of euphoria, excitement, feelings of empathy, stimulation and 
enhanced awareness. Some users have reported repeated use over long periods 
(more than 40 lifetime occasions of use). 3-MMC is a controlled substance in 
several countries in various regions.
Therapeutic usefulness
3-MMC has no known medical applications.
Recommendation
The Committee deliberated at length regarding the information pertinent to the 
degree of risk to public health and society associated with the abuse of 3-MMC 
(2-(methylamino)-1-(3-methylphenyl)propan-1-one). The Committee decided 
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that the information available, and the ensuing discussions, were inadequate to 
enable a consensus and a confident recommendation regarding the scheduling of 
3-MMC. As per paragraph 59 of the Guidance on the WHO review of psychoactive 
substances for international control (2), and as supported by its procedural reference 
to the thirty-fourth report of the WHO Expert Committee on Drug Dependence 
(11), “in cases where additional information concerning the substance under 
review is required, the Committee may decide that it will reach a final opinion at 
a subsequent meeting. ... then it should request another critical review in order 
to refer the matter to a subsequent Expert Committee.” In accordance with these 
guidelines, the Committee requested that the Secretariat arrange another critical 
review of 3-MMC at a subsequent meeting of the Expert Committee.
5.5 Ethylone (3,4-methylenedioxy-N-ethylcathinone; bk-MDEA; 
MEDEC)
Substance identification
Chemically, ethylone is 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-
one. It is a chiral compound with isomers, and its hydrochloride salt can exist in 
two conformations (polymorphs) at the C–C bond linking the side chain to the 
aromatic ring.
Previous review
Ethylone has not previously been pre-reviewed or critically reviewed. A direct 
critical review was proposed based on information brought to the attention of 
WHO that ethylone is clandestinely manufactured, poses a serious risk to public 
health and society, and has no recognized therapeutic use by any Party.
Similarity to known substances and effects on the central nervous system
Ethylone can be considered a slight chemical modification of methylone 
(3,4-methylenedioxymethcathinone), which is included in Schedule II of the 
Convention on Psychotropic Substances of 1971. However, it would be likely 
to be inefficient to intentionally synthesize ethylone to convert it to methylone. 
Similar to cocaine-like drugs, ethylone has relatively nonselective monoamine 
uptake inhibition at dopamine, serotonin and norepinephrine transporters. It 
substitutes completely for the methamphetamine and cocaine discriminative 
stimuli in rats suggesting that it would be likely to produce their subjective 
effects. Reported clinical effects (often observed when accompanied by other 
drugs) include impaired driving, slurred speech, bloodshot watery eyes, dilated 
pupils, involuntary muscle movements and elevated pulse and blood pressure.
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Dependence potential
No controlled studies in humans or laboratory animals regarding the potential 
physical dependence effects of ethylone have been reported.
Actual abuse and/or evidence of likelihood of abuse
Results of controlled laboratory studies in animals or humans characterizing 
the abuse potential of ethylone have not been reported. Seizures of ethylone, 
or its detection in biosamples, have been reported from several countries and 
regions. Within the first six months of 2015, ethylone had become the 12th most 
confiscated drug in the United States. Ethylone is aggressively marketed on the 
Internet and has been sold as a bath salt, plant food and cleaning product. Users 
report administering the drug via the oral, rectal, insufflation, sublingual and 
intravenous routes. Ethylone has been associated with deaths (more than eight 
reports). Several countries in different regions have imposed regulatory controls 
over ethylone.
Therapeutic usefulness
Ethylone was originally patented for its potential antidepressant and 
antiparkinsonian properties in 1995, but no currently approved medical 
applications exist for it.
Recommendation
The Committee considered that the degree of risk to public health and society 
associated with the abuse of ethylone (1-(2H-1,3-benzodioxol-5-yl)-2-
(ethylamino)propan-1-one) is substantial. Therapeutic usefulness has not been 
recorded. It recognized that ethylone has similar abuse and similar ill-effects to 
substances in Schedule II of the Convention on Psychotropic Substances of 1971. 
The Committee considered that there is sufficient evidence that ethylone is being 
or is likely to be abused so as to constitute a public health and social problem 
warranting the placing of the substance under international control. As per the 
Guidance on the WHO review of psychoactive substances for international control 
(2), higher regard was accorded to the substantial public health risk than to the 
lack of therapeutic usefulness. The Committee recommended that ethylone be 
placed in Schedule II of the Convention on Psychotropic Substances of 1971.
5.6 Pentedrone (α-methylaminovalerophenone)
Substance identification
Chemically, pentedrone is 2-(methylamino)-1-phenylpentan-1-one. It has a 
chiral centre giving rise to two stereoisomers, (S)- and (R)-pentedrone.
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Previous review
Pentedrone has not been previously pre-reviewed or critically reviewed by the 
Committee. A direct critical review was proposed based on information brought 
to WHO’s attention that pentedrone is clandestinely manufactured, poses a 
serious risk to public health and society, and has no recognized therapeutic use 
by any Party.
Similarity to known substances and effects on the central nervous system
Pentedrone is a substituted phenethylamine derivative that belongs to the class of 
cathinones, many of which are controlled under the Convention on Psychotropic 
Substances of 1971. It is unlikely that pentedrone could easily be converted into 
an existing controlled substance. Pentedrone binds to the dopamine and to the 
noradrenergic transporters and inhibits dopamine and noradrenergic uptake, but 
binds poorly to the serotonergic transporter and does not meaningfully inhibit 
serotonergic uptake. It induces climbing behaviour, increases locomotor activity 
and produces conditioned place preference in mice, and maintains intravenous 
self-administration in rats. These in vitro and in vivo effects are consistent with 
a profile similar to an abused stimulant such as methamphetamine. Importantly, 
it generalizes to cocaine and to methamphetamine in rat discrimination 
tests, suggesting that it can produce their subjective effects and has an abuse 
liability similar to these drugs. Non-fatal intoxications have been reported, and 
pentedrone has been associated with several DUID cases, although typically 
accompanied by other drugs. Responses to the WHO questionnaire for review 
of psychoactive substances for the thirty-eighth meeting of the ECDD indicated 
that the adverse effects experienced by people who present with pentedrone 
intoxication at emergency departments include impaired consciousness, 
tachycardia, hypotension, nausea, vertigo, hallucinations, high body temperature 
and sweating. Users of pentedrone report MDMA-like stimulating effects, such 
as euphoria, openness and increased sociability and sexual drive.
Pentedrone has been associated with at least six fatalities, although other 
drugs were present in each case.
Dependence potential
No controlled studies in humans or laboratory animals regarding the potential 
physical dependence effects of pentedrone have been reported.
Actual abuse and/or evidence of likelihood of abuse
Pentedrone has been detected in commercial products or in biosamples in Canada, 
several European countries and in the United States. Hundreds of kilograms 
of pentedrone have been seized in the European Union alone. User reports 
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indicate that pentedrone is administered via the oral, insufflation, inhalation and 
intravenous routes. Several countries in different regions have placed pentedrone 
under national control.
Therapeutic usefulness
No therapeutic or medical use has been described for pentedrone.
Recommendation
The Committee considered that the degree of risk to public health and society 
associated with the abuse of pentedrone (2-(methylamino)-1-phenylpentan-1-
one) is substantial. Therapeutic usefulness has not been recorded. It recognized 
that pentedrone has similar abuse and similar ill-effects to substances in Schedule 
II of the UN Convention on Psychotropic Substances of 1971. The Committee 
considered that there is sufficient evidence that pentedrone is being or is likely to 
be abused so as to constitute a public health and social problem warranting the 
placing of the substance under international control. As per the Guidance on the 
WHO review of psychoactive substances for international control (2), higher regard 
was accorded to the substantial public health risk than to the lack of therapeutic 
usefulness. The Committee recommended that pentedrone be placed in Schedule 
II of the UN Convention on Psychotropic Substances of 1971.
5.7 Ethylphenidate (EPH)
Substance identification
Chemically, ethylphenidate is ethyl phenyl(piperidin-2-yl)acetate.
Previous review
Ethylphenidate has not previously been pre-reviewed or critically reviewed. A 
direct critical review was proposed based on information brought to the attention 
of WHO that ethylphenidate is clandestinely manufactured, poses a serious risk 
to public health and society, and has no recognized therapeutic use by any Party.
Similarity to known substances and effects on the central nervous system
Ethylphenidate is a structural analogue of methylphenidate, which is controlled 
as a Schedule II substance under the UN Convention on Psychotropic Substances 
of 1971. Ethylphenidate can be converted into methylphenidate and vice 
versa. Ethylphenidate is also produced as a metabolite from the co-ingestion 
of methylphenidate and alcohol (ethanol), and it has been suggested as one 
determinant of co-abuse of these substances. Ethylphenidate is a selective and 
potent dopamine uptake inhibitor. It is more potent than cocaine in inhibiting 
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dopamine uptake, and also more selective than cocaine for the dopamine relative 
to the noradrenergic or serotonergic transporters. Similar to psychostimulants, it 
increases locomotor activity in rodents and can induce stereotypies. Ethylphenidate 
has clinical effects typical of amphetamine-like stimulants, including tachycardia, 
hypertension, dilated pupils, palpitations, fever, anxiety, agitation, paranoia and 
tremor. Ethylphenidate use has been associated with deaths due to mixed drug 
toxicity, and in one documented instance, ethylphenidate alone was detected.
Dependence potential
No controlled studies in humans or laboratory animals regarding the potential 
physical dependence effects of ethylphenidate have been reported. One brief case 
study has been published describing an individual who developed dependence 
on ethylphenidate purchased from the Internet. The subject had previously been 
dependent on cannabis, heroin/morphine and had occasionally used stimulants.
Actual abuse and/or evidence of likelihood of abuse
Ethylphenidate is sold over the Internet and discussed on drug-user websites, and 
has been identified in confiscated material. Routes of administration reported 
by users include nasal insufflation, oral, anal, vapour inhalation and intravenous 
injection. Users report an immediate and intense rush of pleasurable stimulation, 
which is characterized by alertness and a general mood lift. Other effects reported 
include increased self-confidence, improved ability to focus and concentrate, and 
enhanced social interaction and social skills. The pro-social effects appear similar 
to those reported by users of MDMA. Users on Internet forums report tolerance 
to some of its effects, leading to use of a higher drug dose to achieve the same 
effect and also describe a strong urge to re-dose. Ethylphenidate has been placed 
under national control in several countries in different regions.
Therapeutic usefulness
There are currently no known therapeutic applications for ethylphenidate.
Recommendation
The Committee considered that the degree of risk to public health and society 
associated with the abuse of ethylphenidate (ethyl phenyl(piperidin-2-yl)acetate) 
is substantial. Therapeutic usefulness has not been recorded. It recognized that 
ethylphenidate has similar abuse and similar ill-effects to substances in Schedule 
II of the UN Convention on Psychotropic Substances of 1971. The Committee 
considered that there is sufficient evidence that ethylphenidate is being or is likely 
to be abused so as to constitute a public health and social problem warranting the 
placing of the substance under international control. As per the Guidance on the 
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WHO review of psychoactive substances for international control (2), higher regard 
was accorded to the substantial public health risk than to the lack of therapeutic 
usefulness. The Committee recommended that ethylphenidate be placed in 
Schedule II under the UN Convention on Psychotropic Substances of 1971.
5.8 Methiopropamine (MPA)
Substance identification
Chemically, methiopropamine is N-methyl-1-(thiophen-2-yl)propan-2-amine. It 
has a chiral centre with two enantiomers.
Previous review
Methiopropamine was previously critically reviewed by the Committee 
at its thirty-sixth meeting. Owing to the insufficiency of data regarding 
dependence, abuse and risks to public health, the Committee recommended that 
methiopropamine not be placed under international control at that time but be 
kept under surveillance. Subsequent data collected from the literature and from 
different countries indicating that this substance may cause substantial harm and 
that it has no medical use warranted an updated critical review.
Similarity to known substances and effects on the central nervous system
Methiopropamine is a thiophene analogue of methamphetamine, but is not 
readily converted into other controlled substances. It increases the synaptic levels 
of dopamine and noradrenaline, an effect similar to that of methamphetamine. 
Also similar to methamphetamine, it increases locomotor activity and induces its 
sensitization in mice. Adverse effects reported following administration include 
tachycardia, anxiety, panic attacks, perspiration, headache, nausea, difficulty in 
breathing, vomiting, difficulty urinating and sexual dysfunction. Case reports 
indicate that methiopropamine induces palpitations, chest tightness, anxiety, 
nausea, vomiting and visual hallucinations. Methiopropamine has been associated 
with 62 deaths; in at least 14 of these it was thought to have contributed to death 
even though other drugs were present. One death was thought to be solely related 
to methiopropamine use.
Dependence potential
No controlled studies in humans or laboratory animals regarding the potential 
physical dependence effects of methiopropamine have been reported. 
Actual abuse and/or evidence of likelihood of abuse
Methiopropamine is sold on Internet websites as a “research chemical” or in 
branded products, predominantly in powder form. Methiopropamine abuse has 
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been reported in many countries in different regions. Users report administering 
methiopropamine by insufflation, inhalation or the oral route. Case reports 
and user reports indicate that methiopropamine displays similar properties to 
methamphetamine, including stimulation, alertness and increase of focus and 
energy as well as talkativeness. Methiopropamine has been placed under national 
control in a number of countries in different regions.
Therapeutic usefulness
There are currently no known therapeutic applications for methiopropamine.
Recommendation
The Committee considered that the degree of risk to public health and society 
associated with the abuse of methiopropamine (N-methyl-1-(thiophen-2-yl)
propan-2-amine) is substantial. Therapeutic usefulness has not been recorded. 
It recognized that methiopropamine has similar abuse and similar ill-effects to 
substances in Schedule II of the UN Convention on Psychotropic Substances 
of 1971. The Committee considered that there is sufficient evidence that 
methiopropamine is being or is likely to be abused so as to constitute a public 
health and social problem warranting the placing of the substance under 
international control. As per the Guidance on the WHO review of psychoactive 
substances for international control (2), higher regard was accorded to the 
substantial public health risk than to the lack of therapeutic usefulness. The 
Committee recommended that methiopropamine be placed in Schedule II under 
the UN Convention on Psychotropic Substances of 1971.
5.9 MDMB-CHMICA
Substance identification
Chemically, MDMB-CHMICA is methyl N-{[1-(cyclohexylmethyl)-1H-indol-3-
yl]carbonyl}-3-methyl-L-valinate. MDMB-CHMICA has a chiral carbon in the 
butanoic chain. Therefore, two stereoisomers exist: (S)-MDMB-CHMICA and 
(R)-MDMB-CHMICA.
Previous review
MDMB-CHMICA has not been previously pre-reviewed or critically reviewed. 
A direct critical review was proposed based on information brought to the 
attention of WHO that MDMB-CHMICA is clandestinely manufactured, poses 
a serious risk to public health and society, and has no recognized therapeutic 
use by any Party.
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Similarity to known substances and effects on the central nervous system
MDMB-CHMICA belongs to the group of synthetic cannabinoid receptor 
agonists (SCRAs). MDMB-CHMICA has been shown to activate CB1 and CB2 
cannabinoid receptors with preference for CB1 receptors over CB2 receptors. 
MDMB-CHMICA is a highly efficacious compound with full agonist properties at 
the CB1 receptor of the endocannabinoid system and with a greater potency than 
delta-9-tetrahydrocannabinol (THC). Few reports of pharmacodynamic studies 
in laboratory animals or humans are available that describe the pharmacology 
of MDMB-CHMICA. Case reports and user reports indicate that MDMB-
CHMICA can induce acute toxicity and serious adverse events including nausea, 
confusion, agitation, hallucinations, loss of consciousness, emesis, bradycardia 
or tachycardia, spontaneous urination and defecation, respiratory insufficiency 
and acidosis, hypothermia, mydriasis, hypoglycaemia and seizures including 
tonic–clonic seizures. MDMB-CHMICA has been associated with 53 analytically 
confirmed cases of serious adverse events in Europe and at least 28 deaths. While 
in most instances other drugs (typically other SCRAs) were also present, MDMB-
CHMICA was the sole substance detected in some cases.
Dependence potential
No controlled studies in humans or laboratory animals regarding the potential 
physical dependence or tolerance effects of MDMB-CHMICA have been 
reported. Withdrawal-like symptoms associated with abstinence from MDMB-
CHMICA such as numbing of skin, cravings, mental fog, depressed mood, nausea 
and abdominal pain have been reported by poison information centres and on 
user websites. However, information on duration of use, pattern and amount 
consumed over time was not available.
Actual abuse and/or evidence of likelihood of abuse
There are no available reports of controlled studies involving the dependence 
potential or abuse potential of MDMB-CHMICA in laboratory animals or 
human subjects. Epidemiological reports of the incidence and prevalence of 
MDMB-CHMICA use are also apparently unavailable. MDMB-CHMICA is 
easily purchased on the Internet. It is sold online as a commercially branded legal 
high or as a research chemical in various countries in different regions. More 
than 3600 seizures or reports of detection of MDMB-CHMICA in 21 European 
countries were reported in February 2016. In addition to the non-fatal and fatal 
intoxications, analytically confirmed MDMB-CHMICA use has been related to 
DUID and violent public behaviour. A number of countries in different regions 
have placed MDMB-CHMICA under some level of national control.
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Therapeutic usefulness
There are no known approved therapeutic applications for MDMB-CHMICA.
Recommendation
The Committee considered that the degree of risk to public health and society 
associated with the abuse of MDMB-CHMICA (methyl N-{[1-(cyclohexylmethyl)-
1H-indol-3-yl]carbonyl}-3-methyl-L-valinate) is substantial. Therapeutic 
usefulness has not been recorded. It recognized that MDMB-CHMICA has 
similar abuse and similar ill-effects to substances in Schedule II of the UN 
Convention on Psychotropic Substances of 1971. The Committee considered 
that there is sufficient evidence that MDMB-CHMICA is being or is likely to 
be abused so as to constitute a public health and social problem warranting the 
placing of the substance under international control. As per the Guidance on the 
WHO review of psychoactive substances for international control (2), higher regard 
was accorded to the substantial public health risk than to the lack of therapeutic 
usefulness. The Committee recommended that MDMB-CHMICA be placed in 
Schedule II under the UN Convention on Psychotropic Substances of 1971.
5.10 5F-APINACA (5F-AKB-48)
Substance identification
Chemically, 5F-APINACA is N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-
indazole-3-carboxamide.
Previous review
5F-APINACA has not been previously pre-reviewed or critically reviewed by the 
Committee. A direct critical review was proposed based on information brought 
to the attention of WHO that 5F-APINACA is clandestinely manufactured, poses 
a serious risk to public health and society, and has no recognized therapeutic use 
by any Party.
Similarity to known substances and effects on the central nervous system
5F-APINACA (5F-AKB-48) is an analogue of APINACA (AKB-48) fluorinated 
on the terminal carbon of the pentyl chain. 5F-APINACA binds to cannabinoid 
CB1 and CB2 receptors with greater potency than THC and activates the CB1 
receptor as a full agonist. 5F APINACA induces a prolonged release of dopamine 
in the shell of the nucleus accumbens in awake mice. The CB1 cannabinoid 
receptor antagonist/inverse agonist, AM251, blocks several in vivo effects 
of 5F-APINACA in mice including its induced spontaneous and stimulated 
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aggressiveness, hypothermic effects and antinociceptive effects. The in vitro 
binding and functional activity effects of 5F-APINACA, together with its in vivo 
effects of hypothermia, and cataleptic and antinociceptive effects that are blocked 
by AM251, are consistent with a THC-like cannabinoid compound. In contrast 
to THC, high doses of 5F-APINACA induce spontaneous and handling-induced 
convulsions, hyperreflexia and myoclonus in mice. Anxiety, paranoia, dry mouth, 
headache and hyperthermia have been reported by users of 5F-APINACA on 
blogs and forums. Recently, there have been a number of reports of non-fatal 
intoxications involving 5F-APINACA in several countries. Adverse events 
described in one analytically confirmed case report were agitation, tachycardia, 
hypertension, twitching and chest pain.
Dependence potential
No controlled studies in humans or laboratory animals regarding the potential of 
5F-APINACA to produce physical dependence or tolerance have been reported. 
Users report acute physical withdrawal symptoms when attempting to reduce 
use, including chest pains, chest pressure, tachycardia and palpitations, lower 
extremity pain and spasms, nausea, sweating, diarrhoea and vomiting, which were 
easily resolved by resuming smoking of 5F-APINACA. Psychological withdrawal 
symptoms included insomnia (for more than 3 weeks), internal restlessness, urge 
to re-dose, anxiety, agitation and paranoia.
 Following initial use of between one and four grams per day of herbal 
mixtures containing 5F-APINACA, users report that the amount used increases 
quickly. Compulsive re-dosing occurs despite recognition of loss of control, 
awareness of tolerance and fears about adverse effects. The development of 
thoughts about smoking and cravings first thing in the morning can occur rapidly 
following initial patterns of use of 5F-APINACA.
Actual abuse and/or evidence of likelihood of abuse
5F-APINACA is sold over the Internet. It has been detected in commercial or 
seized products in several countries in different regions. One country reported 
four DUID cases in which 5F-APINACA was detected. A number of countries 
are directly controlling 5F-APINACA under national legislation.
Therapeutic usefulness
There are no known approved therapeutic applications for 5F-APINACA.
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Recommendation
The Committee considered that the degree of risk to public health and 
society associated with the abuse of 5F-APINACA (N-(adamantan-1-yl)-1-
(5-fluoropentyl)-1H-indazole-3-carboxamide) is substantial. Therapeutic 
usefulness has not been recorded. It recognized that 5F-APINACA has similar 
abuse and similar ill-effects to substances in Schedule II of the UN Convention 
on Psychotropic Substances of 1971. The Committee considered that there is 
sufficient evidence that 5F-APINACA is being or is likely to be abused so as 
to constitute a public health and social problem warranting the placing of the 
substance under international control. As per the Guidance on the WHO review 
of psychoactive substances for international control (2), higher regard was accorded 
to the substantial public health risk than to the lack of therapeutic usefulness. The 
Committee recommended that 5F-APINACA be placed in Schedule II under the 
UN Convention on Psychotropic Substances of 1971.
5.11 JWH-073
Substance identification
Chemically, JWH-073 is (1-butyl-1H-indol-3-yl)(1-naphthyl)methanone.
Previous review
During its thirty-sixth meeting, the WHO ECDD had discussed the critical 
review report on JWH-073 and concluded that owing to the insufficiency of data 
regarding dependence, abuse and risks to public health, JWH-073 should not be 
placed under international control at that time but be kept under surveillance. 
New information on its pharmacology and abuse potential warranted an update 
of the critical review report for discussion at the thirty-eighth meeting of the 
ECDD.
Similarity to known substances and effects on the central nervous system
JWH-073 is a homologue of JWH-018, which has been included in Schedule II of 
the Convention on Psychotropic Substances of 1971 since 2015. JWH-073 binds 
to the CB1 and CB2 cannabinoid receptors and exhibits functional in vitro activity. 
Several metabolites of JWH-073 also bind to the CB1 receptor. Similar to THC, 
JWH-073 induces marked hypothermia in mice, increases the pain threshold 
to both noxious mechanical and thermal stimuli, causes catalepsy, reduces 
motor activity, and stimulates dopamine release in the nucleus accumbens in a 
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dose-dependent manner after systemic administration. In addition, it impairs 
sensorimotor responses (visual, acoustic and tactile), causes seizures, myoclonia 
and hyperreflexia, and promotes aggression. All these effects are fully prevented 
by the selective CB1 receptor antagonist/inverse agonist, AM251. Repeated 
administration of JWH-073 can induce tolerance to some of its effects, and 
repeated administration of THC can produce cross-tolerance to some of the 
effects of JWH-073. Users have reported anxiety, tremulousness and palpitations. 
One user reported that she felt like she was “becoming psychotic”. Potency is 
reported to be about half that of JWH-018. There have been several reports of 
patients presenting with analytically confirmed JWH-073 consumption. These 
patients exhibited some of the following signs: chest pain, tachycardia followed 
by bradycardia, hypertension, agitation, paranoia and delusions, abdominal 
cramps with nausea and vomiting, anxiety and tremulousness. However, these 
reports typically involved the presence of other drugs and it is difficult to draw 
a direct linkage between these adverse effects and JWH-073. No fatal cases in 
which JWH-073 was detected in postmortem samples have been reported so far.
Dependence potential
No controlled studies in humans or laboratory animals regarding the potential 
physical dependence or tolerance effects of JWH-073 have been reported.
Actual abuse and/or evidence of likelihood of abuse
In rats and rhesus monkeys, JWH-073 produces the discriminative stimulus effects 
of THC. Additionally, both THC and JWH-073 substitute for the discriminative 
stimulus effects of JWH-018 in mice. Repeated administration of THC, however, 
produces tolerance to its discriminative effects in rhesus monkeys, but not cross-
tolerance to JWH-073. In common with THC, JWH-073 is not self-administered 
by rats.
 JWH-073 is sold over the Internet and has been sold as an additive in 
commercially available “herbal mixtures”. It is sold as a powder or, when sold in 
herbal mixtures, the chemical has been sprayed onto plant material (e.g. damiana 
(Turnera diffusa)). Based on user reports and on the dosage forms offered, the 
primary route of administration is inhalation either by smoking the herbal 
mixture as a “joint” or using a vaporizer, bong or pipe. Abuse has been reported 
in a number of countries in different regions. A number of countries in different 
regions have placed JWH-073 under national control.
Therapeutic usefulness
There are no known approved therapeutic applications for JWH-073.
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Recommendation
The available pharmacodynamic data related to JWH-073 (1-butyl-1H-indol-3-
yl)(1-naphthyl)methanone) demonstrate that this substance has the capacity to 
produce some effects similar to its homologue, JWH-018, which is included in 
Schedule II of the UN Convention on Psychotropic Substances of 1971. However, 
the data currently available do not make it possible to establish a direct link 
between JWH-073 abuse and appearance of public health and social problems 
that would be a requirement for placing this substance under international 
control. It is therefore recommended not to place JWH-073 under international 
control but to continue to keep it under surveillance.
5.12  XLR-11
Substance identification
Chemically, XLR-11 is [1-(5-fluoropentyl)-1H-indol-3-yl]
(2,2,3,3-tetramethylcyclopropyl)methanone.
Previous review
XLR-11 has not previously been pre-reviewed or critically reviewed. A direct 
critical review was proposed based on information brought to WHO’s attention 
that XLR-11 is clandestinely manufactured, poses a serious risk to public health 
and society, and has no recognized therapeutic use by any Party.
Similarity to known substances and effects on the central nervous system
Metabolites of XLR-11 include UR-144, a compound recognized for its own abuse 
potential. XLR-11 binds to cannabinoid CB1 and CB2 receptors with greater affinity 
than THC. XLR-11 acts as a full agonist at both these receptors. XLR-11 produces 
all four effects in the THC tetrad test in the mouse, all components of which, 
except catalepsy, are antagonized by the CB1 receptor antagonist, rimonabant. 
Adverse effects associated with XLR-11 use include nausea, vomiting, low body 
temperature, rigid muscle tone, back and abdominal pain, hypertension, slurred 
speech, lack of convergence, and body and eyelid tremors. Of particular concern 
was the reported association of XLR-11 use and acute kidney injury in users 
who had been hospitalized. Analytically determined use of XLR-11 has been 
confirmed in DUID cases. Confirmed presence of XLR-11 has been associated 
with two deaths.
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Dependence potential
No controlled studies in humans or laboratory animals regarding the potential 
physical dependence or tolerance effects of XLR-11 have been reported.
Actual abuse and/or evidence of likelihood of abuse
XLR-11 produces THC-like discriminative stimulus effects in mice and rats 
indicating that it would be able to produce THC’s subjective effects and that it is 
likely have a similar abuse potential. The discriminative stimulus effects of XLR-
11 are antagonized by rimonabant. XLR-11 is often sold in the form of herbal 
mixtures designed for smoking purposes. XLR-11 has been encountered in 
seizures or as an abused substance in a number of countries in different regions. 
XLR-11 has been placed under national control in a number of countries and 
different regions.
Therapeutic usefulness
There are no approved therapeutic applications for the clinical use of XLR-11.
Recommendation
The Committee considered that the degree of risk to public health and 
society associated with the abuse of XLR-11 ([1-(5-fluoropentyl)-1H-indol-
3-yl](2,2,3,3-tetramethylcyclopropyl)methanone) is substantial. Therapeutic 
usefulness has not been recorded. It recognized that XLR-11 has similar abuse 
and similar ill-effects to substances in Schedule II of the UN Convention on 
Psychotropic Substances of 1971, such as JWH-018 and AM-2201. The Committee 
considered that there is sufficient evidence that XLR-11 is being or is likely to 
be abused so as to constitute a public health and social problem warranting the 
placing of the substance under international control. As per the Guidance on the 
WHO review of psychoactive substances for international control (2), higher regard 
was accorded to the substantial public health risk than to the lack of therapeutic 
usefulness. The Committee recommended that XLR-11 be placed in Schedule II 
under the UN Convention on Psychotropic Substances of 1971.
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6. Updates
6.1 Cannabis and cannabis resin
At its thirty-seventh meeting the ECDD requested the Secretariat to begin 
collecting data that would inform a pre-review of cannabis, cannabis resin, 
extracts and tinctures of cannabis, at a future meeting. In accordance with this 
request, two updates on the scientific literature on cannabis were prepared and 
subsequently presented to the Expert Committee: 
 1) Abuse and dependence potential of Cannabis sativa and nabiximols; 
and 
 2) Systematic reviews on the therapeutic efficacy and safety of cannabis 
(including extracts and tinctures) for patients with multiple sclerosis, 
chronic neuropathic pain, tics associated with Tourette syndrome, HIV/
AIDS, and cancer patients receiving chemotherapy. 
The Committee then discussed the content of the material presented.
In addition to the WHO-commissioned reports, the Committee was 
made aware of other reports submitted to the Secretariat.
Recommendation
The Committee noted that the current Schedule I of the Single Convention on 
Narcotic Drugs of 1961 groups together cannabis and cannabis resin, extracts 
and tinctures of cannabis. Cannabis plant and cannabis resin are also in Schedule 
IV of the 1961 Convention. The Committee further noted that there are natural 
and synthetic cannabinoids in Schedule I and Schedule II of the Convention on 
Psychotropic Substances of 1971.
The Committee recognized:
 ■ an increase in the use of cannabis and its components for medical 
purposes;
 ■ the emergence of new cannabis-related pharmaceutical preparations 
for therapeutic use;
 ■ that cannabis has never been subject to a formal pre-review or critical 
review by the ECDD.
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The Committee requested that the Secretariat prepare relevant 
documentation in accordance with the Guidance on the WHO review of 
psychoactive substances for international control (2) in order to conduct pre-
reviews for the following substances:
 ■ cannabis plant and cannabis resin
 ■ extracts and tinctures of cannabis
 ■ delta-9-tetrahydrocannabinol (THC)
 ■ cannabidiol (CBD)
 ■ stereoisomers of THC
The Committee recommended that these pre-reviews be evaluated at a specific 
ECDD meeting dedicated to cannabis and its component substances to be held 
within 18 months of the thirty-eighth meeting.
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7. Follow-up on recommendations from international 
meetings and consultations
7.1 Follow-up on implementation of recommendations of 
UNGASS and of the UNODC-WHO Expert Consultation on NPS
Dr Lopato provided an introduction to the implementation of recommendations 
of the UNGASS on the world drug problem by describing how Resolution S-30/1 
(9) adopted by the UNGASS on 19 April 2016 entitled, “Our joint commitment 
to effectively addressing and countering the world drug problem”, included 
operational recommendations responding to new psychoactive substance abuse. 
One of the recommendations specified:
Share relevant information with … and strengthen the capacity of the World Health 
Organization, the United Nations Office on Drugs and Crime, the International 
Narcotics Control Board and other relevant international and regional organizations 
to prioritize the review of the most prevalent, persistent and harmful new 
psychoactive substances and to facilitate informed scheduling decisions by the 
Commission on Narcotic Drugs. 
Another operational recommendation on NPS pertained to surveillance 
and specified:
Actively participate in early warning networks and promote the use of relevant 
surveillance lists and voluntary controls and the sharing of information through 
the International Narcotics Control Board, the United Nations Office on Drugs and 
Crime and the World Health Organization... and enhance bilateral, subregional, 
regional and international cooperation in the identification and reporting of new 
psychoactive substances and incidents involving such substances.
Dr Lopato informed the Committee that WHO had held several meetings 
after the UNGASS 2016 during which the recommendations on NPS were 
discussed. These meetings included the third UNODC-WHO Expert Consultation 
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on NPS that took place on 3 and 4 May 2016 at WHO headquarters, where the 
prioritization of the most harmful, prevalent and persistent NPS for evaluation 
by the ECDD was discussed. In addition to collecting data for prioritization from 
the INCB, UNODC, EMCDDA, the UMC and Member States, it was proposed 
to include other international organizations in the prioritization process (e.g. 
the World Customs Organization and Interpol). This would facilitate collection 
of data on confiscations and seizures as indicators for market presence. It was 
also proposed to increase Member States’ contributions. It was noted that the 
availability of reference standards and established standardized methodologies 
for identification were necessary to improve forensic laboratory capacity for 
detection and identification of NPS.
Dr Lopato emphasized that an efficient early warning system (EWS) relies 
on continuous and dynamic data collection at the national and regional levels, 
which then feed into an international EWS. It was mentioned that the network for 
data exchange needs two-way communication. Effective and timely notification of 
health-related risks involving the use of NPS was also considered important. The 
publication of surveys, reports and results of scientific studies was encouraged, 
as evidence-based information should be disseminated. Improving the quality of 
data was also considered critical for future evaluation of psychoactive substances.
 Dr Justice Tettey, Observer from the UNODC, provided a summary of 
the above-mentioned third UNODC-WHO Expert Consultation on NPS held 
in Geneva in May 2016, following CND resolution 58/7. It had brought together 
experts from international and regional organizations and subject-matter experts 
to explore practical ways for collecting robust data for the prioritization of the 
most harmful NPS, as well as for establishing efficient surveillance systems. 
In the context of UNODC’s mandates, the Expert Consultation made further 
recommendations on strengthening national forensic and law enforcement 
capacity to aid in the identification and detection of NPS.
Dr Tettey informed the Committee on progress made since the Expert 
Consultation in promoting effective international exchange of information for 
identifying the most harmful, prevalent and persistent NPS. An international 
Expert Consultation on forensic toxicology and drug control held in Vienna, 
Austria, in June 2016, had resulted in a successful pilot exercise to develop a tool 
to collect and disseminate toxicological data on adverse health consequences and 
fatalities associated with NPS use. The UNODC EWA on NPS will be expanded 
to include a system for collecting and disseminating information on the harm 
caused by NPS.
Dr Tettey further described ongoing activities to improve the capacity 
of national drug testing laboratories. These included UNODC’s international 
collaborative exercises, the provision of reference standards, guidance on the 
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laboratory analysis of NPS, and workshops and training. The enhancement of 
law enforcement capacity to detect NPS is being pursued through a number 
of national and regional training workshops conducted through the SMART 
programme, as well as through the provision of drug detection kits for use in 
the field.
7.2 WHO and other agencies’ surveillance mechanisms and lists
Dr Lopato briefed the Committee on the WHO surveillance mechanisms and list. 
She described the CND resolution 59/8 (March 2016) (11) which invited WHO, 
with the support of UNODC, relevant regional organizations and Member States, 
to disseminate its surveillance list of substances of concern, in order to proactively 
collect evidence on these substances to support future evidence-based reviews 
and for issuing public health alerts when there is sufficient evidence that a new 
psychoactive substance poses a risk to public safety. Dr Lopato’s briefing touched 
on several points.
There is a need to establish a new surveillance system at the international 
level to facilitate the scheduling process and to respond effectively to prevent 
harm to public health arising from the use of NPS. The maintenance of a WHO 
surveillance list (with special attention to NPS) would allow information to be 
collated that could then be used to inform future ECDD deliberations as well as 
in the process of prioritizing substances for review.
 Currently, 11 substances are being kept under WHO surveillance, 10 
of which were critically reviewed by the ECDD at its thirty-sixth meeting in 
2014 and one that was reviewed at its thirty-seventh meeting in 2015. As there 
was insufficient evidence on harm and risks to health arising from use of these 
substances at the time of the review, the Committee recommended that they 
should not be placed under international control, but be kept under surveillance. 
Substances in the current WHO surveillance list had been considered during 
the prioritization process for their possible evaluation by the ECDD at its thirty-
eighth meeting.
A surveillance system was discussed during the third UNODC-WHO 
Expert Consultation on NPS and at the meeting of the first Informal Working 
Group of the ECDD in May 2016. After consideration, it was proposed that a 
list of substances under surveillance by WHO should be actively maintained 
through the proactive collection of data from international organizations (e.g. 
UNODC, the INCB and the World Customs Union), regional organizations 
(e.g. EMCDDA) and national observatories and Member States. WHO should 
accumulate data continuously. This will mainly rely on collaborative arrangements 
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with multiple organizations and bodies, including UNODC (e.g. through the 
SMART programme and the EWA on NPS), the EMCDDA (EU EWS), and other 
regional organizations and Member States.
Information potentially useful in placing a substance under surveillance 
includes: the known or likely mechanism of action relevant to predicting that 
significant adverse events can be expected; direct evidence of adverse effects 
such as forensic data regarding overdose events; fatal and non-fatal intoxications; 
laboratory data that are predictive of adverse events; and reports coming directly 
from users or health authorities in contact with users (with some evidence that 
the substance in question is correctly identified).
The primary criteria for harm would be fatalities, in addition to other 
serious adverse events (e.g. non-fatal intoxications) and other public health 
risks (e.g. reports of DUID and harm to others). Other criteria and data for 
consideration would include available pharmacological information and context 
or mode of use. It was emphasized that there must also be criteria for excluding 
substances from the WHO surveillance list.
 Dr Lopato explained that numerous important challenges need to be faced 
in the satisfactory maintenance of a surveillance list, including the development 
of a pipeline for health-related data from Member States, maintaining a database 
on a large number of frequently changing substances, developing criteria to be 
used for inclusion of a substance in the surveillance list, determining conditions 
for issuing a health alert on a substance, deciding how much information is to be 
included about each substance on the list, and disseminating the surveillance list 
and health alerts.
 Dr Lopato concluded by noting that the updated surveillance list would 
be published on the ECDD website.
Ms Beate Hammond, Observer from the INCB, presented an update on 
the INCB’s international operations on NPS, known as Project ION. The objective 
of Project ION is to reduce the supply of NPS and therefore prevent them from 
reaching consumer markets. In this way the project contributes to preventing 
harm to human health. Project ION has received political support from the 
international community in CND resolution 59/8 (6) and, most recently, in the 
UNGASS outcome document. In the six months preceding the ECDD meeting, 
the number of people using IONICS, the incident communication system 
for the exchange of information on NPS, as well as the number of incidents 
communicated had increased by more than 25%.
In cooperation with UNODC, the INCB was organizing a conference 
on NPS in Bangkok in early 2017 to take stock of achievements and discuss the 
challenges ahead. It was expected that the conference would result in the adoption 
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of an outcome document and operational recommendations that will translate 
UNGASS commitments into actions. Future plans included an intelligence-
gathering survey on opioid-type NPS which have been causing serious harm to 
health in North America and a time-bound operation on NPS in other regions.
The INCB also has an NPS surveillance list that is regularly updated, as the 
prevalence of substances can change quickly and some substances will be placed 
under international control. Although the list is not compiled for scheduling 
purposes, several of the substances have now been scheduled or are being 
reviewed by the ECDD.
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8. Future agenda items
The Committee agreed that it would request that the Secretariat arrange a critical 
review of 3-MMC for a subsequent Expert Committee meeting.
In addition, the Committee requested that the Secretariat prepare pre-
review documentation on cannabis-related substances. The following specific 
pre-reviews were requested:
 ■ cannabis plant and cannabis resin
 ■ extracts and tinctures of cannabis
 ■ delta-9-tetrahydrocannabinol (THC)
 ■ cannabidiol (CBD)
 ■ stereoisomers of THC.
The Committee recommended that these pre-reviews be evaluated at a specific 
ECDD meeting dedicated to cannabis and its component substances to be held 
within the 18 months following the thirty-eighth meeting.
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This report presents the recommendations of the thirty-
eighth WHO Expert Committee on Drug Dependence 
(ECDD). The ECDD is responsible for the assessment of 
psychoactive substances for possible scheduling under 
the international drug control conventions. The ECDD 
reviews the therapeutic usefulness, the liability for abuse 
and dependence, and the public health and social harm 
of each substance. The ECDD will advise the Director-
General of WHO, to schedule or to amend the scheduling 
status of a substance. The Director General will, as 
appropriate, communicate the recommendations to the 
Secretary-General of the United Nations, who will in turn 
communicate the advice to the Commission on Narcotic 
Drugs (CND). 
The report summarizes the review of twelve substances 
and the ECDD recommendations for the scheduling of 
ten substances. Furthermore, the ECDD discussion and 
recommendation for pre-reviews of pre-reviews of cannabis 
and its component substances are included in this report. 
The report also contains updates from international bodies 
concerned with controlled substances, as well as summaries 
of the follow up on the recommendations made at the 
previous Committee meeting, and on the discussions of 
prioritization of substances, surveillance systems of new 
psychoactive substances and terminology. Issues identified 
for consideration at future Expert Committee meetings are 
also listed.  
